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ABSTRACT
Background: Treatment effect is traditionally assessed
through either superiority or non-inferiority clinical
trials. Investigators may ﬁnd that because of safety
concerns and/or wide variability across strata of the
superiority margin of active controls over placebo,
neither a superiority nor a non-inferiority trial design is
ethical or practical in some disease populations. Prior
knowledge may allow and drive study designers to
consider more sophisticated designs for a clinical trial.
Design: In this paper, the authors propose hybrid
designs which may combine a superiority design in
one subgroup with a non-inferiority design in another
subgroup or combine designs with different control
regimens in different subgroups in one trial when
a uniform design is unethical or impractical. The
authors show how the hybrid design can be planned
and how inferences can be made. Through two
examples, the authors illustrate the scenarios where
hybrid designs are useful while the conventional
designs are not preferable.
Conclusion: The hybrid design is a useful alternative
to current superiority and non-inferiority designs.
INTRODUCTION
Treatment-effect size is traditionally assessed
through either superiority or non-inferiority
randomised clinical trials. However, because
of safety concerns and/or wide variability
across strata of the superiority margin of
active controls over placebo, neither a supe-
riority nor a non-inferiority trial design is
ethical or practical in some disease popula-
tions. For example, in the development of
a direct-acting antiviral agent (DAA) for
hepatitis C virus (HCV), the phase 3 devel-
opment processes involved one trial in
subjects who are treatment-naı ¨ve and one in
subjects who are treatment-experienced.
Each was a superiority trial at a two-sided
signiﬁcance level of 0.05 comparing the DAA
with Pegylated-interferon plus Ribavirin.
However, the trial for the treatment-experi-
enced population is unethical because the
previous null responders of Pegylated-inter-
feron plus Ribavirin are unlikely to beneﬁt
from the second course of the same treat-
ment and are likely to suffer from its side-
effects. See next section for more details.
One possible solution is to conduct
multiple trials with each trial focusing on one
subgroup. In the previous example, this
would require three trials instead of two: one
trial in subjects who are treatment-naı ¨ve, the
second trial in subjects who are previous null
responders and the third trial in subjects who
are partial responders or responder relapses
(see next section for a clear deﬁnition for
these terms). Traditional practice would be to
conduct each trial at a two-sided signiﬁcance
level of 0.05.
The above design, referred to as a conven-
tional design throughout the paper, consists
of multiple traditional trials, each for one
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ARTICLE SUMMARY
Article focus
- We propose hybrid designs for the trials when
neither a superiority nor a non-inferiority trial
design is ethical and practical.
Key messages
- The hybrid design is practical, ﬂexible and
feasible.
- We expect it to become a major alternative to the
superiority and non-inferiority designs.
Strengths and limitations of this study
- Hybrid design provides a powerful and relatively
simple solution to the difﬁcult problem of active
controls with varying efﬁcacy and/or safety
concern. The problem is becoming more
common as more drugs become available.
- The design and analysis are moderately complex
compared with the superiority and non-inferiority
designs.
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Open Access Researchsubgroup. This conventional design is often neither
necessary nor practical. It is unnecessary because it
requires three trials in a situation where the regulatory
practice is to require only two trials for drug approval
(see next section for details). In fact, the ethic and
feasibility problem shall not change this regulatory
perspective of requiring of two trials. The major practical
problem associated with this conventional design is its
requirement of a sufﬁciently large sample size to power
each of the multiple trials to a designated level (eg,
a power of 80%) and, hence, an increased length of
recruitment and cost. This is a particular problem when
one of the trials requires exclusively recruitment from
some minority subgroups.
For the above practical reasons, it is common in
practice that trials enrol subjects with different reactions
to treatments into the same trial and aim to demonstrate
its overall efﬁcacy. We give two examples. In example 1,
subjects with or without lung disease react differently to
Palivizumab, a prophylaxis in reduction in respiratory
syncytial virus infection in high-risk infants.
1 In a recent
Palivizumab-controlled non-inferiority trial to develop
Motavizumab, a second generation of Palivizumab,
subjects with different lung-disease statuses were
enrolled into one trial.
2 In example 2, it is known that
HIV-infected subjects with different phenotypic sensi-
tivity scores (PSS) react differently to treatments; they
were all enrolled into each of BENCHMRK-1 and
BENCHMRK-2 to evaluate Raltegravir.
34
Consequently, the conventional design would often be
undesirable. As part of efforts to improve drug devel-
opment, we propose a hybrid design, for situations
where the active controls have clinically signiﬁcantly
different margins of superiority to placebo in different
strata of the population. In some of these situations,
a simple design may be unethical; in others, a simple
superiority design may require unrealistically potent new
drugs to beat the active control in strata where the latter
is most effective, while a simple non-inferiority design
may require unrealistically narrow non-inferiority
margins relative to the active control in strata where the
latter is least effective. The hybrid design combines
superiority designs for some subgroups and non-inferi-
ority designs for other groups in one trial. Furthermore,
the non-inferiority designs used in a hybrid design can
be different with different active controls or different
non-inferiority margins in different strata of the popu-
lation. Consequently, in a hybrid design, different
designs are allowed for different subgroups, while the
intended inference for the new treatment is for the
whole population in the trial.
The concept of hybrid design generally refers to new
designs that are formed by combining features of
established designs. In this paper, the hybrid design
refers to a synthesis of a number of superiority and/or
non-inferiority designs (hypotheses) for different
disjoint subgroups in one trial. This concept has also
been used in the area of epidemiology to refer to
a multilevel design which takes advantages of ecological
and analytic studies when examining the association
between exposure and a disease.
5 It has also been used
in the area of social science to refer to new designs, for
example, the Solomon Four-Group Design,
6 formed by
combining existing experimental designs. In the area of
multifactor experimental design for exploring response
surface, hybrid designs, considered as alternatives to
central composite designs, refer to a class of saturated or
near-saturated second-order designs that allow experi-
menters to ﬁt a quadratic model with a minimal or near-
minimal number of runs.
7
We utilise a Fisher combination test to make an overall
inference from all subgroups. In addition, we propose
a general method for sample-size determination and
power calculation in a hybrid design. We demonstrated
its usefulness and advantages over the conventional
design. The hybrid design is naturally related to meta-
analysis, which generally focuses on the data-analysis
stage rather than the design stage.
MOTIVATION EXAMPLES
Approval of new drugs requires either two randomised
clinical trials in which the new drug demonstrates efﬁ-
cacy at a two-sided level 0.05 or one larger trial in which
efﬁcacy is demonstrated at a level comparable with two
trials each at 0.05.
The US FDA generally recommends such a develop-
ment programme to demonstrate efﬁcacy of the new
drug in the broadest possible population. In several drug
areas, for example, HCV and HIV, the current phase 3
development processes involve one trial in subjects who
are treatment-naı ¨ve and another in subjects who are
treatment-experienced. Both trials are active controlled
trials.
In the treatment-naı ¨ve population, the active control
will elicit an excellent response, and a non-inferiority
trial will be conducted. Within the treatment-experi-
enced population, it is not uncommon in our experi-
ence for there to be baseline covariates which identify
strata with substantially different response rates on the
active control. In such circumstances, the natural
method of study may well be to conduct the conven-
tional design consisting of multiple trials. Each trial
targets one stratum. One would use a non-inferiority
design in one trial and a superiority design in the other
trial.
There is one practical problem with this conventional
design: instead of the expected two phase 3 trials, one
has three such trials. Because there is already one phase
3 trial showing efﬁcacy at a two-sided level of 0.05 in the
treatment-naı ¨ve population, the US FDA would approve
a drug in which the evidence of efﬁcacy from one
treatment-experienced trial is 0.05. Therefore, sponsors
(pharmaceutical companies) are reluctant to design
development programmes using the conventional
design which requires more than two phase 3 trials.
Designing multiple trials to achieve a level of 0.05
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required to meet regulatory standards. Consequently,
sponsors often design either one non-inferiority trial or
one superiority trial in a population containing all strata
where the active control is potent and the stratum where
it is weak, even though neither design is truly appro-
priate to both strata. Below, we present two examples to
illustrate the major problems of this practice.
Developing DAA for HCV
Pegylated-interferon plus Ribavirin was the standard of
care (SOC) for HCV-infected subjects. However, SOC
yields to a low response rate for infected subjects with
HCV genotype 1.
8 In addition, its side-effects affect
almost all treated subjects.
9 Concerns about the tolera-
bility and efﬁcacy of SOC have led to recent develop-
ment of the DAA.
It was recommended that a superiority design be used
to demonstrate the superiority of the DAA as an add-on
to SOC comparison to placebo plus SOC.
10 The subjects
to be enrolled are HCV-treatment-naı ¨ve subjects
(subjects received no prior therapy for HCV) or SOC-
experienced subjects including null responders (subjects
had a reduction in HCV RNA of <2 log10 at week 12 of
the previous SOC), partial responders (subjects had
a reduction in HCV RNA of $2 log10 at week 12 of the
previous SOC, but not achieving HCV RNA undetectable
at the end of treatment with an SOC), and responder
relapsers (subjects had HCV RNA undetectable at the
end of treatment with an SOC, but HCV RNA detectable
within 24 weeks of SOC treatment follow-up).
Following this guidance, some sponsors proposed the
development of DAA using one trial for the treatment-
naı ¨ve population and another for the treatment-experi-
enced population. However, some regulatory reviewers
have raised questions regarding the potential ethical
problems. They found that the above recommended
design is feasible for HCV-treatment-naı ¨ve subjects,
partial responders and responder relapsers, but it is
unethical for null responders because there is insufﬁ-
cient beneﬁt with SOC
11 and because of safety concerns.
The conventional design may suggest separating null
responders from the second trial and conducting a third
single arm, a historical controlled trial for the null
responders. The objective is to (1) demonstrate that the
new treatment is efﬁcacious in the trial for partial
responders, and responder relapsers with a statistical
signiﬁcance at a level of 0.05; and (2) demonstrate that
the new treatment is efﬁcacious in the trial for null
responders with a statistical signiﬁcance at a level of 0.05.
This conventional design changed the original objec-
tive. Should there be no ethic concerns, the objective
was to demonstrate that the new treatment is efﬁcacious
in the treatment-experienced population at a level of
0.05, with no need to show statistical signiﬁcance in each
of the two strata at level of 0.05. As we stated earlier,
designing all three trials to achieve a level of 0.05
demands more subjects and expense than is actually
required to meet regulatory standards.
As a new and alternative solution to the trial for
subjects who are treatment-experienced, we propose
using different designs for null responders and others
(partial responders and responder relapsers) in one
single trial. For example, we can enrol all null
responders to the single-arm DAA plus SOC and enrol
all others following the recommended design.
10 For null
responders, the design is to demonstrate that the new
treatment is superior to the SOC based on historical
experience on the response rate of SOC. Consequently,
we used two different designs within the same trial
according to their response status to the previous SOC
treatment. The objective remains to demonstrate that
the new treatment is efﬁcacious in the trial for all
treatment-experienced subjects with a statistical signiﬁ-
cance at a level of 0.05.
Developing new treatment for HIV
Subjects with HIV infection are usually treated with
combinations of three or four drugs from among several
classes: nucleoside reverse transcriptase inhibitors
(NRTI), non-nucleoside reverse transcriptase inhibitors
(NNRTIs), protease inhibitors (PIs), integrase, fusion or
entry inhibitors (IIs, FIs, EIs) to increase the duration of
viral suppression and ﬁnal cure rate, and to reduce the
risk of viral-resistance development.
Although many HIV drugs are currently available,
development of new potent treatment from any inhib-
itor classes is urgently needed to overcome the increased
genetic barrier of drug resistance. HIV viruses mutate
rapidly, and some mutations lead to drug resistance of
current HIV treatments. HIV’s short life-cycle and high
error rate cause the virus to mutate very rapidly, making
it one of the hardest viruses to combat.
The typical design for evaluating a new treatment is to
demonstrate the non-inferiority of the new treatment to
an approved active control as an add-on to optimal
background therapy (OBT) of several drugs. For
example, an evaluation of a new NNRTI, such as Rilpi-
virine for antiviral-naı ¨ve subjects was carried out using
a non-inferiority trial comparing the new treatment with
an approved NNRTI, Efavirenz as an add-on to two
NRTIs (eg, Tenofovir and Emtricitabine).
Consider a new integrase inhibitor tested against
Raltegravir. The phase 3 development processes involves
one trial in subjects who are treatment-naı ¨ve and
a second in subjects who are treatment-experienced.
Both trials are Raltegravir-controlled non-inferiority
trials. The trial in subjects who are treatment-naı ¨ve is
standard, so we focus on the second trial.
In order to deﬁne the non-inferiority margin in
subjects who are treatment-experienced, we need to
quantify the treatment beneﬁt of Raltegravir relative to
the placebo, as an add-on to OBT. Among treatment-
experienced subjects, the subject’s virus may be resistant
to many or all candidate drugs for the OBT. The PSS is
a measure of the number of drugs in an OBT to which
the subject’s virus is not yet resistant at baseline and is
a good predictor of the duration of viral suppression by
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over the placebo, as an add-on to an OBT, observed in
the BENCHMRK trials varied in subjects with different
PSS. The response-rate difference between Raltegravir
and placebo changes from 49% in subjects with 0 PSS, to
32% in subjects with PSS between 1 and 2, to 10% in
subjects with PSS $3.
3 41 2
To illustrate the difﬁculty in conducting a single
non-inferiority trial for the treatment-experienced
subjects, we reproduced the subgroup analysis by PSS in
table 1, based on the results presented by Cooper and
colleagues.
3
The overall response rates are 67% and 33% for
Raltegravir and placebo, respectively, as an add-on to
OBT. The treatment beneﬁt of Raltegravir is 34% with
a 95% CI of 26e42%. A ﬁxed margin would deﬁne 13%,
half of the low bound of the CI, as the non-inferiority
margin. This margin seems to be too conservative for
subjects with low PSS and too liberal for subjects with
high PSS. After all, when such a high level of heteroge-
neity occurs, an overall treatment effect may not be
relevant. Furthermore, if the trial has a high percentage
of subjects with high PSS, the non-inferiority margin is
inappropriate. Note that the percentage of subjects
with high PSS is usually unknown at the design stage,
which complicates the situation further. Consequently,
designing a meaningful non-inferiority trial may be
difﬁcult.
Similar to the results presented in table 1, the response
rate of OBT is generally affected by the PSS scores.
12 For
subjects with low PSS, the response rate of OBT is
generally low. For example, the response rate of OBT is
<10% in subjects with 0 PSS. On the other hand, for
subjects with high PSS, the response rate of OBT is
generally high. For example, the response rate is more
than 40% in subjects with PSS $3.
12
Based on the previously described information, we can
design the trial based on our existing knowledge about
HIV drugs and patient populations. We learnt that the
OBT works well for subjects with PSS greater than 2, for
example, and works less well for other subjects. Hence,
we may consider the hybrid design. In one single trial,
we evaluated the superiority of the new treatment as an
add-on to OBT to placebo as a matched add-on to OBT
in subjects with PSS $2, and evaluated the non-inferi-
ority of new treatment as to Raltegravir, as an add-on to
OBT in subjects with PSS smaller than 2. For the supe-
riority hypothesis part, as the OBT leads to a high
response rate in subjects with high PSS, the superiority
trial design for these subjects is ethical. For the non-
inferiority hypothesis part, because the difference in
response rates in Raltegravir and placebo is 0.39 with an
SE of 0.05, a statistical non-inferiority margin can be
deﬁned, for example, as 15%, a half of the lower bound
of a 95% CI (0.30 to 0.49). Note that a superiority trial
for subjects with low PSS is unethical, because OBT leads
to a poor response for these subjects.
The conventional design, which involves two separate
trials for treatment-experienced subjects with high and
low PSS, requires many more subjects than the newly
proposed hybrid design does. As we explained earlier,
the sponsors are reluctant to take the conventional
approach.
HYBRID DESIGN
We expect that more trials similar to those discussed
above cannot be simply implemented as either simple
superiority trials or simple non-inferiority trials owing to
advanced prior knowledgedfor example, side-effects
and heterogeneity of efﬁcacy margins of active control
drugs within different subpopulations. We propose
a hybrid design as an alternative. The hybrid design
allows each subgroup to use a different design.
In general, we assume that there are k disjoint
subgroups in a clinical trial. For these subgroups, k
different designs addressing different hypotheses are
used as components of a hybrid design. These designs
could be superiority, non-inferiority designs, or historical
controlled designs. Alternatively, they could all be supe-
riority or non-inferiority designs but with different
controls.
If the goal is to demonstrate the experimental treat-
ment’s superiority over the placebo in the ith subgroup,
the ith null hypothesis is formatted as H0i: qi¼0, where qi
is the metric measuring the difference between the new
treatment and the control for i ¼ 1, 2, ., k. Note that
the H1i: qi>0 implies the experimental treatment’s
superiority over the placebo. Therefore, for ease of
presentation and without loss of generality, we consider
here only a placebo control superiority design. If the
goal is to demonstrate the non-inferiority of the experi-
mental treatment relative to the active control in the ith
subgroup, the ith null hypothesis is formatted as H0i:
qi¼edi, where qi is the metric measuring the difference
between the new treatment and the control and edi is
the non-inferiority margin, that is a positive value of qi+di
implies the non-inferiority of the new treatment over the
active control. Because the non-inferiority margin d is
Table 1 Subgroup analysis by phenotypic sensitivity scores (PSS)
Treatment Placebo Difference (SE)
PSS¼0 33/65 (51%) 1/44 (2%) 49% (0.066)
PSS¼1 83/137 (61%) 20/69 (29%) 32% (0.069)
PSS¼2 99/139 (71%) 24/62 (39%) 33% (0.073)
PSS¼3 58/82 (71%) 28/46 (61%) 10% (0.088)
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between the active control and the placebo measured in
historical trials, a positive value of qi+di also implies the
superiority of the new treatment over the placebo.
As a summary, although individual hypotheses, either
superiority hypothesis or non-inferiority hypotheses, are
different in all k subgroups, these hypothesis compo-
nents share the same objective to demonstrate that an
experimental treatment is better than a placebo. That is,
the primary objective is to test the null hypothesis, H0:
q¼0, where q is a metric measuring the difference
between the new treatment and the placebo.
A p value was obtained for each subgroup. For
a subgroup conducted as a superiority trial, a p value is
obtained, considering the subgroup as a separate trial.
For a subgroup conducted as a non-inferiority trial, a
p value is obtained using the testing method described
in, for example, Wang et al,
13 again considering the
subgroup as a separate trial. For a subgroup conducted
as a historical controlled trial, a p value can be similarly
obtained.
Similar to the meta-analysis, the Fisher combination
test
14 can be utilised to make statistical inferences for the
hybrid designs. The Fisher combination test, which is
based on the production of p values, was originally
proposed to combine evidence from separate studies. It
applies to analysing the hybrid design naturally.
In a trial where a hybrid design was used, a p value pi
was obtained for the ith subgroup. Some or all of them
may not be signiﬁcant at a prespeciﬁed leveldfor
example, 0.05. This is expected because substudies are
not powered to demonstrate the signiﬁcance. In a hybrid
design, we only want to determine whether the
combined evidence reaches the prespeciﬁed signiﬁcance
level, using the Fisher combination test.
14
The Fisher combination test was introduced to
combine evidence from different subgroups and make
inferences
14 as follows. The null hypothesis that the
experimental treatment is the same as the placebo, is
rejected at a level a if
Y k
i¼1
pi#exp
 
 
1
2
c
2
2k(1 a)
 
;
where c2
2kð1 aÞ denotes the (1ea)-quantile of the c
2
distribution with 2k degrees of freedom.
The advantage of the Fisher combination test is that it
relies only on p values of individual tests. The disad-
vantage of this test is as follows. The Fisher combination
test does not quantify the treatment difference between
treatment groups. In addition, the Fisher combination
test may suffer a loss of power when the sample sizes are
substantially unbalanced over treatments.
15 While the
Fisher test is recommended, some alternative ways
16e20
can also be similarly modiﬁed to make inferences in the
hybrid design. Further research may be needed to
compare different methodologies for inference, which is
beyond the scope of this paper.
POWER CALCULATION
Sample size determination can be based on the Fisher
combination test. For the determination based on the
Fisher combination test, we choose signiﬁcance levels
a1;.;ak and n1;.;nk for individual subgroups and so
that
Y k
i¼1
ai # Ca, where Ca ¼ exp
n
 
1
2
c2
2kð1   aÞ
o
, and
a is the prespeciﬁed type I error rate.
The computation of power can be done based on the
Fisher combination test through the following method.
Let hi be the test statistics used in the ith subgroup; Let
f
ðiÞ
Hi0ðhiÞ and F
ðiÞ
Hi0ðhiÞ be the density function and cumu-
lative distribution function of hi, respectively, when the
true values of parameters are those values given in the
null hypothesis. Similarly, let f
ðiÞ
Hi1ðhiÞ and F
ðiÞ
Hi1ðhiÞ be the
density function and cumulative distribution function of
hi when the true values of parameters are those values
given in the alternative hypothesis. It is easy to show that
the power can be computed through the following
algorithm,
< Randomly generate l¼1,.,m independent samples of
h
ðlÞ
1 ;.;h
ðlÞ
k are using their distribution density func-
tion f
ðiÞ
H11ðh1Þ;.;f
ðkÞ
Hk1ðhkÞ ;
< For all l¼1,.,m, compute
Qk
i¼1f1   F
ðiÞ
Hi0ðh
ðlÞ
i Þg # Ca.
The lth sample is considered as a success if Qk
i¼1f1   F
ðiÞ
Hi0ðh
ðlÞ
i Þg # Ca.
< The power is the percentage of samples which are
success among m samples.
Implementation of this algorithm is simple. For
example, we implement it in SAS, and the computation
is fast even when k is relatively large. The numerical
computation of power can also be carried out based on
the Fisher combination test using the method described
by Banik et al.
15 In their method, the power is calculated
through multiple integration. The drawback of this
method is its computational challenge. The integration
can be difﬁcult, so it is impractical when k is not small.
We propose determining the sample based on the
Fisher combination test for its simplicity, although other
methods could also be feasible. We believe the sample
size determination based on Fisher’s combination test is
generally reasonable. As was suggested previously,
15 we
expect the loss of power to be small compared with the
optimal test, unless the sample sizes are substantially
unbalanced over treatments, which should not appear in
well-controlled clinical trials. The key is, in the planning
stage, we typically try to avoid any substantial imbalance.
NUMERICAL STUDY
In this section, we consider an experiment to support
a new DAA for the treatment of hepatitis C in treatment-
experienced subjects. A conventional design of the
experiment consists of two separate trials: a historical
controlled single-arm trial for null responders and an
SOC-controlled superiority trial of the DAA for partial
responders and responder relapsers. We assume that the
randomisation in the second trial is 1:1. In the hybrid
design, we combine these two trials into one, using the
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comparison as in the conventional design.
We compare the total sample size needed for the
hybrid design with that for the conventional design. For
the hybrid design, the sample size is calculated so that
the whole study has a power of 80% and a two-sided type
I error rate of 0.05. On the other hand, for the
conventional design, the sample size is calculated so that
each trial has a power of 80% and a two-sided type I error
rate of 0.05. The sample size for the conventional design
is implemented in the SAS procedure PROC POWER,
based on the Fisher exact test.
The results are given in table 2. As we expect, and as
the results clearly indicate, the hybrid design typically
requires a signiﬁcantly smaller sample size. Let p0;DAA be
the response rate for the null responses receiving DAA;
let p0;SOC be the historical response rate of null
responders received SOC treatments; let pDAA and pSOC
be the assumed response rate for the partial responses
and relapsers receiving DAA and SOC treatments
respectively. When the p0;DAA ¼ 30%; p0;SOC ¼ 10%,
and pDAA ¼ 40%; pSOC ¼ 20%; the conventional design
suggests enrolling 33 subjects to the single-arm historical
controlled trial for null responders, and 90 subjects to
each treatment group in the active-controlled trial for
partial responders and responder relapsers, so that the
power of each trial is 80%. On the other hand, the
hybrid design proposes enrolling 19 null responders
and 49 partial responders and responder relapsers
in one trial, so that the power of the trial could
have a power of 80%. The result is consistent for all
other cases evaluated. The hybrid design could be
more economic, although the conventional design, if
implemented, will generally provide more information
about each subgroup. We believe that the hybrid is
a useful alternative to conventional designs. Also refer to
ﬁgure 1 for a visual comparison of two designs for
the case p0;DAA ¼ 30%; p0;SOC ¼ 8%, and pDAA ¼ 40%;
pSOC ¼ 15%; table 2.
DISCUSSION
The hybrid design can be a good alternative to an active-
controlled non-inferiority trial when the treatment
heterogeneity of the active control has been observed in
the phase 3 trial leading to the approval of that drug.
Further problems with the non-inferiority margin can
arise when the population of the planned active-control
non-inferiority trial is different from that in the older
trials comparing the active control with placebo. Nie and
Soon attempted to solve the problem, but their method
itself was complex, involving model ﬁtting and model
selection. Furthermore, the implementation of sample-
size determination and power could be challenging, as
Nie and Soon noted.
21 The hybrid design offers a valu-
able alternative to simple non-inferiority trials. The latter
only allows the same control arm and same non-inferi-
ority margin in all strata.
Compared with a conventional design where separate
trials were conducted for subgroups, the hybrid design
can yield sufﬁcient evidence of efﬁcacy for regulatory
approval with a smaller sample size. In addition,
recruiting different subgroups for separate trials results
in unnecessary overhead costs as well as practical difﬁ-
culties. For example, sensitivity scores for the optimal
background regimen in treatment-experienced subjects
will not be known until a substantial amount of
screening has been carried out, even though once the
OBT has been selected and characterised, the sensitivity
scores constitute a stratum for randomisation. The
evaluation on these subgroups can be carried out in the
hybrid design.
Cohort splitting has often been used in social science,
medical topics and observational studies, but the hybrid
design, which combines different designs into one trial,
Figure 1 Conventional design
versus hybrid design to develop
direct-acting antiviral agent (DAA).
HCV, hepatitis C virus.
Table 2 Sample size for conventional and hybrid design
Assumed response rate for null
responders
Assumed response rate partial
responders or relapsers Sample size
Direct-acting
antiviral agent (%)
Standard of care
(historical) (%)
Direct-acting
antiviral agent (%)
Standard
of care (%)
Conventional
design Hybrid design
30 10 40 20 213¼33+180 117¼19+98
30 8 40 15 137¼25+112 76¼14+62
20 10 30 20 724¼100+624 416¼56+360
20 8 30 15 331¼67+264 187¼39+148
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A proposal for a new type of clinical trial: the hybrid designhas never been introduced to clinical trial to date.
Hybrid design is a combination of experimental design
and analysis plan. Cohort-splitting studies most
commonly compare efﬁcacy in studies using the same
endpointdfor example, superiority to placebo as
measured in head-to-head comparisons in different
cohorts. On the other hand, hybrid designs are intended
to permit determinations of efﬁcacy using different
endpoints in different stratadfor example, direct supe-
riority to placebo in one stratum and non-inferiority to
an active control in a different stratum.
As one referee pointed out, a CI approach could be
more informative than the currently proposed p value
approach. While further research on the CI approach is
warranted, it is beyond the scope of this paper.
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